Numinus Wellness Inc (TSE:NUMI) has released an update.
Numinus Wellness Inc., a mental health care company focusing on psychedelic-assisted therapies, has applied for a Clinical Trial with Health Canada to explore group-based MDMA psychotherapy for practitioners. The study aims to understand optimal therapist numbers for safe delivery and could set the stage for best practices in group therapy, enhancing the treatment of PTSD and other serious mental conditions. The groundbreaking research, if approved, represents a significant advance in the integration of psychedelic-assisted treatments into mainstream care.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
